The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting : Reflecting a Changing mRCC Treatment Landscape
The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 22 vom: 08. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doehn, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Everolimus |
|---|
| Anmerkungen: |
Date Revised 13.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14225486 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349415307 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349415307 | ||
| 003 | DE-627 | ||
| 005 | 20231226042552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14225486 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349415307 | ||
| 035 | |a (NLM)36428579 | ||
| 035 | |a (PII)5486 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doehn, Christian |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting |b Reflecting a Changing mRCC Treatment Landscape |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a everolimus | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a non-interventional study | |
| 650 | 4 | |a pazopanib | |
| 650 | 4 | |a real-world data | |
| 650 | 4 | |a renal cell carcinoma | |
| 650 | 4 | |a time on drug | |
| 650 | 4 | |a trial-eligibility | |
| 700 | 1 | |a Bögemann, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Grünwald, Viktor |e verfasserin |4 aut | |
| 700 | 1 | |a Welslau, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Bedke, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Schostak, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ehneß, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Degenkolbe, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Witecy, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Goebell, Peter J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 22 vom: 08. Nov. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:22 |g day:08 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14225486 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 22 |b 08 |c 11 | ||